BRD9 and malignant colon neoplasm: In human colon cancer cells, knockdown of BRD9, pharmacologic inhibition with iBRD9, and targeting of BRD9 overexpression via natural polyphenols resulted in marked changes in phenotype and molecular readouts, whereas normal colonic epithelial cells were resistant.